17 million U.S. adults experience major depressive episodes each year and at least one-third of them are considered treatment resistant. AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of MDD and TRD.
Learn more about Depression and AXS-05
Alzheimer's Disease Agitation
Individuals diagnosed with Alzheimer’s Disease typically experience behavioral and psychological symptoms including agitation and aggression. AXS-05 is a novel, oral, investigational drug product, incorporating multiple mechanisms of action, under development for the treatment of Alzheimer’s disease agitation.
Learn more about Agitation Associated With Alzheimer's Disease and AXS-05